Roche
NEWS
A summary of daily biopharma industry news. Please check out stories that are trending on March 25, 2020.
“The industry is increasing capacities, but at the same time infection rates are even increasing faster,” said Roche CEO Severin Schwan. “At the moment, capacities are limited. That is why we have to prioritize testing to higher risk patients.”
A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.
The company has initiated a late-stage trial assessing its rheumatoid arthritis drug Actemra in patients who have severe COVID-19 caused pneumonia.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
Hospitals and laboratories will be able to run the test on Roche’s fully automated cobas 6800 and cobas 8800 Systems, which are already in wide use in the U.S. and internationally.
The stated cause of the suspension of enrollment was the occurrence of two intrathecal catheter-related infections that weren’t related to the drug.
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.
DIAN-TU-001 is a Phase II/III trial that tested two therapies compared to placebo, Genentech and Roche’s gantenerumab and Eli Lilly and Company’s solanezumab.
JOBS
IN THE PRESS